AA
TLSI icon

AlphaCentric Advisors’s TriSalus Life Sciences TLSI Stock Holding History

AlphaCentric Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$247K Buy
+25,000
New +$248K 0.07% 90

Other funds holding TLSI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

AlphaCentric Advisors's TLSI Position: Q4 2021 in Review

AlphaCentric Advisors opened a new position in TriSalus Life Sciences (TLSI) in Q4 2021: 25,000 shares worth $247K. The stake represents 0.07% of the portfolio and ranks #90 among its holdings.

68 funds tracked by Wall St. Rank hold TLSI as of Q4 2021.

  • AlphaCentric Advisors held 25,000 shares of TriSalus Life Sciences worth $247K as of Q4 2021.
  • TriSalus Life Sciences was a new AlphaCentric Advisors position in Q4 2021.
  • TriSalus Life Sciences made up 0.07% of AlphaCentric Advisors's portfolio in Q4 2021, its #90 holding.
  • 68 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.